DRUG
metreleptin
0.1 mg/kg/day once a day via subcutaneous injections
Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Status
Completed
Phase
Phase 2
Enrollment
9
Locations
1
Results
Posted
Publications
1
Study summary
What the protocol is testing.
Nonalcoholic steatohepatitis (or NASH) is known to be caused by deposition of fat in the liver and development of scarring. This condition occurs more frequently in overweight and obese persons. It is often associated with resistance to the actions of insulin hormone. Fat cells secrete a hormone called leptin. Recently, we have learned that obese or overweight persons make too much leptin, which may contribute to insulin resistance. Paradoxically, patients who do not have any fat cells, also have insulin resistance. In these patients, insulin resistance is caused by the absence of leptin and leptin replacement significantly improves insulin resistance and fat deposition in the liver. In an earlier study, we determined the leptin levels in patients with NASH and how these levels are related to body fat levels as well as responsiveness to insulin. We saw that a subgroup of patients with NASH have relatively low levels of leptin in contrast to the amount of body fat they had. We now would like to see if restoring leptin levels to normal will improve the disease process in these patients. Our study patients will be male patients, aged between 18 and 65 (inclusive), who do not have any other cause for their liver disease. We have put some restrictions in body size such that a spectrum of patients from normal weight to obese range would be included. They will also demonstrate low leptin levels (levels similar to only 25% of normal population). We will use a genetically engineered form of leptin manufactured by Amylin Inc. given via injections under the skin. We plan to continue therapy for a period of one year and evaluate the change in liver disease by a liver biopsy. We will also follow the metabolic parameters and body composition characteristics that we examined in our earlier study. We expect that patients with low blood leptin levels will show improvement in their liver disease and insulin resistance when their blood leptin levels are restored to normal.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jan 17, 2008
Study start
Feb 2006
Primary completion
Mar 2009
Study completion
Mar 2009
Results posted
Dec 9, 2016
Registry updated
Nov 24, 2017
Outcomes
What the study measures.
Primary outcomes
Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months
Time frame · 1 year
Non-alcoholic steatohepatitis (NASH) score after approximately one year of treatment with metreleptin. Total NASH scores can range from 0 to 14. The higher the NASH score the more severe the liver disease.
Secondary outcomes
Body Weight at 12 Months
Time frame · 1 year
Body weight (kg) after one year of treatment on metreleptin for patients that completed 12 months of metreleptin treatment.
Liver Fat Percentage by Magnetic Resonance Imaging (MRI - Dixon Method) at 12 Months
Time frame · 1 year
For determination of hepatic fat content by MRI and MR spectroscopy in patients, a series of out-phase and in-phase MRI at multiple flip angles are used. By combination of out-phase and in-phase MRI at multiple flip-angles and TE times, relaxation-time effects can be removed to yield quantitative intra-hepatic (and other organs') fractional fat content throughout the liver in a few breath-hold intervals.
Liver Function Test: Alanine Aminotransferase (ALT) Values at 12 Months
Time frame · 1 year
ALT value in subjects that completed 12 months of metreleptin treatment.
Liver Function Test: Aspartate Aminotransferase (AST) Values at 12 Months
Time frame · 1 year
AST value in subjects that completed 12 months of metreleptin treatment.
Fasting Glucose Value at 12 Months
Time frame · 1 year
Fasting glucose value in subjects that completed 12 months of metreleptin treatment.
Fasting Triglycerides Value at 12 Months
Time frame · 1 year
Fasting triglyceride value in subjects that completed 12 months of metreleptin treatment.
Insulin Resistance: Homeostatic Model Assessment (HOMA) at 12 Months
Time frame · 1 year
HOMA values in subjects that completed 12 months of metreleptin treatment.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- MALE
- Healthy volunteers
- No
Inclusion Criteria: * Biopsy proven NASH * Circulating fasting leptin \<9 ng/mL (staggered criteria for different BMI levels) Exclusion Criteria: * Presence of advanced liver disease (as evidenced by abnormal synthetic function, abnormal prothrombin time or albumin) * Presence of clinical lipodystrophy * Presence of other liver disease * Presence of clinical diabetes (fasting \>126 mg/dL or 2 hour post 75 g-glucose \>200 mg/dL or random glucose \>200 mg/dL with presence of diabetes symptoms or known history of diabetes) * Any medication for treatment of NASH or obesity * Presence of HIV * Inability to give informed consent * Presence of end-stage renal disease, any type of active cancer, or \>class 2 congestive heart failure ((New York Heart Association Functional Classification System), based on medical history and physical examination * Presence of any other condition that limits life expectancy to \<2 years * Active infection (may be transient) * Any other condition in the opinion of the investigators that may impede successful data collection
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
University of Michigan
Ann Arbor, Michigan, United States
Related trials
More studies on Metreleptin.
NCT IDStudyPhase / statusEnrollmentUpdated
Metreleptin in Anorexia Nervosa
Gabriella Milos · Anorexia Nervosa
Phase 2
Recruiting
50
2026-07
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Regeneron · Generalized Lipodystrophy
Phase 3
Completed
9
2026-07
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Diabetes · Lipodystrophy
Phase 2
Active, not recruiting
29
2026-07
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Amryt Pharma · Generalized Lipodystrophy
Phase 3
Terminated
1
2026-07
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Lipodystrophy · Diabetes
Phase 3
Active, not recruiting
24
2026-07
MEASuRE: Metreleptin Effectiveness And Safety Registry
Chiesi Farmaceutici S.p.A. · Generalised Lipodystrophy · Partial Lipodystrophy
Not applicable
Recruiting
100
2026-07
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Chiesi Farmaceutici S.p.A. · Familial Partial Lipodystrophy
Phase 3
Recruiting
24
2026-07
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Chiesi Farmaceutici S.p.A. · Partial Lipodystrophy
Phase 3
Active, not recruiting
69
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.